Ting-Ting Fang

East China University of Science and Technology

Papers

1

Total Citations

142

H-Index

1

About

Ting-Ting Fang is a pioneering researcher at the intersection of synthetic biology and gastrointestinal disease, best known for engineering living therapeutics. Her landmark 2022 study, cited over 140 times, introduced a biomarker-responsive probiotic that not only diagnoses and records inflammatory bowel disease (IBD) in mice but also actively ameliorates it—a breakthrough in "smart" bacterial therapies. This work exemplifies her core contributions: designing genetically engineered microbes that sense disease-specific signals, process information, and deliver targeted treatments, effectively turning probiotics into programmable diagnostic and therapeutic platforms. Fang’s research has reshaped how we approach chronic inflammatory conditions, offering a non-invasive, real-time alternative to conventional drugs. Her impact is reflected in the rapid citation of her work, signaling its foundational role in the emerging field of living diagnostics. Beyond IBD, her innovations hold promise for other gut-linked disorders, positioning her as a leader in translating synthetic biology from bench to bedside. For students and researchers, Fang’s work is a compelling model of how interdisciplinary thinking—merging microbiology, genetic circuits, and medicine—can create transformative tools for precision health.

Research Focus

Key Achievements

1
H-Index
1
Papers
142
Total Citations
142
Avg Citations/Paper
🏆 Most Cited Paper
Biomarker-responsive engineered probiotic diagnoses, records, and ameliorates inflammatory bowel disease in mice
142 citations · 2022
📈 Most Prolific Year: 2022 (1 Papers)
🤝 Key Collaborators: 4
🏛 Institutions: East China University of Science and Technology

Top Papers

  1. 1

Key Collaborators

Contact & Links

Available for collaboration
Content generated · 11 days ago